N-(4-(cyclohexylamino)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,2,2-trifluoroacetamide | 1310730-50-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-(cyclohexylamino)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,2,2-trifluoroacetamide
• 英文别名: N-[4-(cyclohexylamino)-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridin-5-yl]-2,2,2-trifluoroacetamide
• CAS: 1310730-50-7
• 化学式: C₂₂H₂₃F₃N₄O₃S
• 分子量: 480.511
• InChiKey: PUQVJUZUXOONEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-(4-(cyclohexylamino)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,2,2-trifluoroacetamide 在 1-丙基磷酸酐 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以68%的产率得到1-cyclohexyl-6-tosyl-2- (trifluoromethyl)-1,6- dihydroimidazo[4,5-d]pyrrolo[2,3- b]pyridine
  参考文献：
  名称：

  Design and synthesis of tricyclic cores for kinase inhibition

  摘要：

  Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.108
• 作为产物：
  描述：

  4-chloro-5-nitro-1-tosyl-1H-pyrrolo[2,3-b]pyridine 在 tin(II) chloride dihdyrate 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.67h， 生成 N-(4-(cyclohexylamino)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  Design and synthesis of tricyclic cores for kinase inhibition

  摘要：

  Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.108

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES INNOVANTS
  申请人：ABBOTT LAB

  公开号：WO2011068881A1

  公开（公告）日：2011-06-09

  The invention provides compounds of Formula (I) and Formula (II), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了Formula (I)和Formula (II)的化合物，以及在此定义的变量的药用可接受盐、前药、生物活性代谢物、立体异构体和同分异构体。该发明的化合物对于治疗免疫和肿瘤疾病是有用的。
• Novel Tricyclic Compounds
  申请人：WISHART Neil

  公开号：US20110311474A1

  公开（公告）日：2011-12-22

  The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供式（I）和式（II）的化合物，以及药物可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此定义。本发明的化合物可用于治疗免疫和肿瘤疾病。
• Tricyclic compounds
  申请人：Wishart Neil

  公开号：US08426411B2

  公开（公告）日：2013-04-23

  The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供式(I)和式(II)的化合物，以及其药学上可接受的盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此定义。本发明的化合物可用于治疗免疫和肿瘤病症。
• NOVEL TRICYCLIC COMPOUNDS
  申请人：Wishart Neil

  公开号：US20130216497A1

  公开（公告）日：2013-08-22

  The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供公式（I）和公式（II）的化合物，其制剂可接受的盐，前药，生物活性代谢物，立体异构体和同分异构体，其中变量在此定义。本发明的化合物可用于治疗免疫和肿瘤疾病。
• US8426411B2
  申请人：——

  公开号：US8426411B2

  公开（公告）日：2013-04-23